The aim is to develop next-generation targeted alpha radiation therapies by further developing Akiram’s CD44v6 platform with advanced pretargeting technology and innovative radiolabeling, the company states.

PRE-CISE

PRE-CISE is a Eurostars-funded collaborative project with a total of EUR 1 million in funding. Preclinical results are expected to be available in 2026.

PRE-CISE is based on a combination of Akiram’s CD44v6-targeting antibody platform, PreTT’s expertise in pretargeting technology and TetraKit’s radiolabeling platform. With a two-step approach – where the antibody first binds to the tumor and the radioactive component is delivered separately – the conditions are created to use alpha-emitting radionuclides that cannot normally be combined with traditional antibody-based treatments. The strategy can increase accuracy while reducing the impact on healthy tissue.

This is an important step towards broadening our pipeline beyond beta-emitting therapies.

“By separating the targeting phase from the therapeutic phase, we create new conditions for developing more precise and effective cancer treatments,” says Marika Nestor, CEO of Akiram Therapeutics. “This innovative treatment principle builds on our CD44v6 platform and is an important step towards broadening our pipeline beyond beta-emitting therapies.”